摘要
目的探讨强化阿托伐他汀治疗经皮冠状动脉介入术后对比剂肾病的临床价值。方法选择2016年7月至2017年7月烟台市莱阳中心医院收治冠状动脉性心脏病行经皮冠状动脉介入术后对比剂肾病患者94例为研究对象，按照随机数字表法分为观察组与对照组各47例，观察组行阿托伐他汀强化治疗，对照组口服空白胶囊进行对照，比较干预前后两组肾功能变化情况，及干预后临床症状消失时间。结果干预后，观察组尿素氮及血肌酐水平分别为（6.1±0.3）mmol/L和（81.5±5.5）μmol/L，均显著优于干预前的（26.5±2.9）mmol/L和（491.5±25.6）μmol/L（t＝47.970、104.730，均P〈0.05）及干预后对照组的（13.9±2.0）mmol/L和（265.7±31.8）μmol/L（t＝26.441、39.130，均P〈0.05）；干预后观察组蛋白尿恢复正常时间、低蛋白血症恢复正常时间、水肿消退时间及血脂恢复正常时间分别为（11.3±1.1）d、（21.3±2.1）d、（4.1±0.3）d和（45.3±3.6）d，均显著短于对照组的（13.5±1.3）d、（23.8±2.6）d、（5.6±0.4）d和（62.3±4.2）d（t＝9.803、5.979、21.503、17.481，均P〈0.05）。结论针对经皮冠状动脉介入术后对比剂肾病，使用阿托伐他汀强化治疗，能有效保护患者肾功能，改善临床症状，值得临床推广。
Objective To investigate the protective effect of atorvastatin on patients with contrastor nephropathy after percutaneous coronary intervention（PCI）.Methods From July 2016 to July 2017, 94 patients with nephropathy in Laiyang Central Hospital were enrolled in this study.The patients were randomly divided into two groups, with 47 cases in each group.The observation group received atorvastatin intensive treatment, and the control group was treated with blank capsule.The changes of renal function before and after intervention, and the recovery time of clinical symptoms after intervention were compared.Results After intervention, the blood urea nitrogen and serum creatinine levels of the observation group were （6.1±0.3）mmol/L and （81.5±5.5）μmol/L, respectively, which were significantly lower those than before intervention [（26.5±2.9）mmol/L, （491.5±25.6）μmol/L]（t=47.970, 104.730, all P〈0.05） and those of the control group after intervention [（13.9±2.0）mmol/L, （265.7±31.8） μmol/L]（t=26.441, 39.130, all P〈0.05）. After intervention, the recovery time of proteinuria, hypoalbuminemia, and edema disappeared time, normal blood lipid recovery time in the observation group were （11.3±1.1）d, （21.3±2.1）d, （4.1±0.3）d and （45.3±3.6）d, respectively, which were significantly shorter than those in the control group[（13.5±1.3）d, （23.8±2.6）d, （5.6±0.4）d, （62.3±4.2）d]（t=9.803, 5.979, 21.503, 17.481, all P〈0.05）.Conclusion For the contrast agent nephropathy, the use of atorvastatin intensive therapy can effectively protect the patients＇ renal function, improve the clinical symptoms, which is worthy of clinical promotion.
作者
于春英
王焕泰
Yu Chunying;Wang Huantai(Department of Cardiology,Laiyang Central Hospital,Yantai,Shandong 265200,Chin;Department of Neurology,Laiyang Central Hospital,Yantai,Shandong 265200,China)
出处
《中国基层医药》
CAS
2018年第21期2808-2810,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
肾病
冠状动脉疾病
放射学
介入性
造影剂
强化治疗
阿托伐他汀
Nephrosis
Coronary artery disease
Radiology
interventional
Contrast media
Intensive Therapy
Atorvastatin
